Chimeric Monoclonal Antibodies Infliximab Cas 170277-31-3
Chimeric Monoclonal Antibodies Infliximab Cas 170277-31-3
| Product name:Infliximab | Purity:95% min |
| CAS NO:170277-31-3 | Solubility:DMSO : ≥ 15.32mg/mL |
| Molecular Formula:C6428H9912N1694O1987S46 | Package:Package according to customer requirements |
| Molecular Weight:144190.3 g/mol | Storage:Store at -20℃ |
Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.It is used off-label outside its FDA approval for Behçet's disease and other conditions. Infliximab is administered by intravenous infusion, typically at six- to eight-week intervals. It cannot be given by mouth because the digestive system would destroy the drug.
Related Prodcuts:
Pembrolimumab; Secukinumab; Ramucirumab; Ipilimumab; Atezolizumab; Daratumumab; Dulaglutide; Rituximab; Adalimumab; Nivolumab; Denosumab; Cetuximab; Bevacizumab; Aflibercept
- [1] Lucia A Méndez-García, et al. Scand J Immunol. 2018 Nov;88(5):e12716.
- [2] Isamu Yamakawa, et al. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52.
- [3] Minami Uchida, et al. Front Microbiol. 2019 Sep 18;10:2148.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.